Pan-canceR Early-Stage deteCtion by lIquid Biopsy tEchNique projecT

Inclusion Criteria for All the Participants: * Ability to provide a written informed consent * 40-75 years old Exclusion Criteria for All the Participants: * Inability to comply with study procedures * Pregnancy or lactating women * Recipients of organ transplant or prior non-autologous (allogeneic) bone marrow transplant or stem cell transplant * Recipients of blood transfusion within 7 days prior to study blood draw * Recipients of any anti-cancer therapy within 30 days prior to study blood draw, due to diseases other than cancer Inclusion Criteria for Cancer Arm Participants: * Confirmed diagnosis or suspicious cases of one of the 22 types of malignancies within 42 days prior to study blood draw * No prior or ongoing anti-cancer therapy (local or systematic) prior to study blood draw Exclusion Criteria for Cancer Arm Participants: * Known prior diagnosis of malignancies * Other current malignant diseases or multiple primary tumors * No confirmed diagnosis of cancer by histopathological or radiological assessments within 42 days of study blood draw, or diagnosis of a benign disease by histopathological assessments, or inability to characterize whether the lesion is malignant or benign * Non-small-cell lung cancer patients with ground-class nodularity by radiological examination Inclusion Criteria for Benign Diseases Arm Participants: * Confirmed diagnosis of benign diseases corresponding to the tumor types in the Cancer Arm by histopathological or radiological assessments within 90 days prior to study blood draw * No prior treatment of benign diseases prior to study blood draw Exclusion Criteria for Benign Diseases Arm Participants: * History of malignancies * Current malignancies or precancerous lesions * No confirmed diagnosis of a benign disease by radiological, endoscopic or histopathological assessments within 42 days of study blood draw, or inability to characterize whether the lesion is malignant or benign Inclusion Criteria for Non-tumor (Healthy) Arm Participants: * No cancer-related symptoms or discomfort within 30 days prior to study blood draw * No clinically significant finding by LDCT or ultrasound * No clinically significant finding by breast ultrasound or Molybdenum Target Mammography Detection, or Thinprep cytologic test (TCT) detection for female participants * No active hepatitis B or hepatitis C infection Exclusion Criteria for Non-tumor (Healthy) Arm Participants: * Prior or ongoing treatment of cancer within 3 years prior to study blood draw * Clinically significant or uncontrolled comorbidities